<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01411657</url>
  </required_header>
  <id_info>
    <org_study_id>20090300</org_study_id>
    <nct_id>NCT01411657</nct_id>
  </id_info>
  <brief_title>NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey L Goldberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ciliary Neurotrophic Factor (CNTF) has been demonstrated in multiple preclinical models to&#xD;
      enhance survival and regeneration of retinal ganglion cells, the retinal neurons injured in&#xD;
      diseases like ischemic optic neuropathy/optic nerve stroke. We hypothesize that CNTF delivery&#xD;
      to the human eye will provide neuroprotection (prevent loss of vision) and neuroenhancement&#xD;
      (improve vision indices) in ischemic optic neuropathy. Patients in the trial will receive an&#xD;
      NT-501 CNTF implant (made by Neurotech) into one eye, and will be carefully followed to&#xD;
      evaluate safety and efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Number of patients with adverse events</measure>
    <time_frame>18 months</time_frame>
    <description>Safety will be evaluated by determining the number of patients with adverse events, including loss of vision, visual field, or retinal/optic nerve structure, and ocular complications such as pain and inflammation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Efficacy: Vision, Visual Field, Pattern Electroretinogram, Visual Field Questionnaire-25</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural efficacy: Nerve fiber layer, optic nerve topography</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Ischemic Optic Neuropathy/Optic Nerve Stroke</condition>
  <arm_group>
    <arm_group_label>NT-501 CNTF Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive single NT-501 CNTF implant in one eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NT-501 CNTF Implant</intervention_name>
    <description>Single implantation of CNTF-secreting NT-501 device into one eye</description>
    <arm_group_label>NT-501 CNTF Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 40 years or older&#xD;
&#xD;
          -  must understand and sign the informed consent&#xD;
&#xD;
          -  must be medically able to undergo ophthalmic surgery for the NT-501 device insertion&#xD;
             and possible removal, as well as the testing required.&#xD;
&#xD;
          -  diagnosis of ischemic optic neuropathy characterized by (a) non-arteritic subtype,&#xD;
             including a normal ESR and CRP; (b) syndrome of acute unilateral visual loss with&#xD;
             documented optic nerve head edema but without significant pain; (c) a relative&#xD;
             afferent papillary defect in the affected eye, and a decrease of best-corrected visual&#xD;
             acuity to 20/40 or worse in the affected eye, and detectable loss on visual field&#xD;
             testing consistent with nerve fiber visual field defect but retaining measurable&#xD;
             residual visual field preservation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other corneal, lens, optic nerve or retinal disease causing vision loss,&#xD;
&#xD;
          -  blind in one eye&#xD;
&#xD;
          -  requirement of acyclovir and/or related products during study&#xD;
&#xD;
          -  receiving systemic steroids or other immunosuppressive medications.&#xD;
&#xD;
          -  pregnant or lactating.&#xD;
&#xD;
          -  considered immunodeficient or has a known history of human immunodeficiency virus&#xD;
             (HIV)&#xD;
&#xD;
          -  on chemotherapy, or a history of malignancy, UNLESS it was treated successfully 2&#xD;
             years prior to inclusion in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute, University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 5, 2011</study_first_submitted>
  <study_first_submitted_qc>August 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2011</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jeffrey L Goldberg</investigator_full_name>
    <investigator_title>Associate Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Neuropathy, Ischemic</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

